Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish ...

With all the buzzwords surrounding artificial intelligence, from smiling promotions to angry chagrins—promises that it will ...

Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...

Earlier this month, Medtronic received a new approval from the FDA for its decades-old liquid embolic system, extending its ...

Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the ...

After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...

After taking a shot at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical ...

A new mental health-driven biotech has arrived in Syremis Therapeutics. | Founded by a team of neuropsychiatric-focused Teva ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory ...